Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | 3.00M | 19.64M | 859.00K | 3.85M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 3.00M | 19.64M | 859.00K | 3.85M | |
| Cost of Revenue | 15.34M | 16.66M | 14.29M | 13.29M | |
| Gross Profit | -12.34M | 2.98M | -13.43M | -9.45M | |
| SG&A Expenses | 10.28M | 20.26M | 15.67M | 3.42M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 25.62M | 36.92M | 29.96M | 16.71M | |
| Operating Income | -22.62M | -17.28M | -29.10M | -12.86M | |
| Income Before Tax | -20.19M | -16.63M | -29.10M | -12.88M | |
| Income Tax Expenses | -- | -- | 34.00K | -- | |
| Earnings from Continuing Operations | -20.19M | -16.63M | -29.14M | -12.88M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -20.19M | -16.63M | -29.14M | -12.88M | |
| EBIT | -22.62M | -17.28M | -29.10M | -12.86M | |
| EBITDA | -22.28M | -17.13M | -28.98M | -12.79M | |
| EPS Basic | -1.18 | -0.97 | -1.88 | -0.75 | |
| Normalized Basic EPS | -0.74 | -0.61 | -1.17 | -0.47 | |
| EPS Diluted | -1.18 | -0.97 | -1.88 | -0.75 | |
| Normalized Diluted EPS | -0.74 | -0.61 | -1.17 | -0.47 | |
| Average Basic Shares Outstanding | 17.11M | 17.11M | 15.52M | 17.11M | |
| Average Diluted Shares Outstanding | 17.11M | 17.11M | 15.52M | 17.11M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |